Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$806.14 USD

806.14
3,911,551

-12.79 (-1.56%)

Updated Nov 4, 2024 04:00 PM ET

Pre-Market: $803.24 -2.90 (-0.36%) 9:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

M&A Activities Intensify in Pharma Industry

M&A Activities Intensify in Pharma Industry.

Mark Vickery headshot

No Econ Data, but Big Biopharma News

Merck, Gilead and Lilly make progress on an otherwise slow news day.

Satsuma Plunges on Disappointing Data on Migraine Treatment

Satsuma (STSA) tanks as late-stage study of STS101 (dihydroergotamine [DHE] nasal) powder as an acute treatment for migraine disappoints.

Benjamin Rains headshot

3 Safe Blue Chip Stocks to Buy as Market Bounces Back After Tech Selloff

There could be more selling ahead and the election might cause turbulence. Nonetheless, long-term investors might want to consider adding a few safe blue chip stocks to their portfolios...

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $151.97, marking a +1.78% move from the previous day.

The Zacks Analyst Blog Highlights: DIS, NVO, BHP, AVGO and LLY

The Zacks Analyst Blog Highlights: DIS, NVO, BHP, AVGO and LLY

AVEO Acquires Full Global Rights to Ficlatuzumab From Biodesix

AVEO reclaims complete rights to ficlatuzumab from Biodesix for an undisclosed sum. The candidate is being developed for several cancer indications.

Sheraz Mian headshot

Top Research Reports for Disney, Novo Nordisk & BHP

Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Novo Nordisk (NVO) and BHP Group (BHP).

Kinjel Shah headshot

Pharma Stock Roundup: SNY, GSK, AZN's Coronavirus Vaccines/Treatments Progress

AstraZeneca (AZN) begins phase III study on COVID-19 vaccine candidate in the United States. Sanofi (SNY)/Glaxo's (GSK) vaccine enters clinical stage.

Lilly (LLY) Gets FDA Approval for Higher Doses of Trulicity

Lilly's (LLY) higher doses of Trulicity led to superior reductions in blood glucose level and weight in type II diabetes patients compared to the currently available dose.

Eli Lilly (LLY) Stock Moves -0.35%: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $149.02, marking a -0.35% move from the previous day.

AstraZeneca's Farxiga Betters Survival in Renal Outcome Study

AstraZeneca's (AZN) Farxiga significantly reduces the risk of kidney failure and cardiovascular or death in patients with chronic kidney disease.

Why Eli Lilly (LLY) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Why Is Lilly (LLY) Down 3.7% Since Last Earnings Report?

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Radhika Pujara headshot

Workday (WDAY) Tops on Q2 Earnings & Revenues, Stock Rises

Workday's (WDAY) fiscal second-quarter results benefit from a high demand for its cloud-based HCM and financial management solutions, and synergies from the Scout RFP acquisition.

Kinjel Shah headshot

Pharma Stock Roundup: SNY, JNJ Acquisition Deals, FDA Approvals

J&J (JNJ) proposes to buy Momenta Pharmaceuticals while Sanofi (SNY) offers to buy Principia Biopharma

United Therapeutics Announces FDA Acceptance of Tyvaso sNDA

United Therapeutics' (UTHR) INCREASE study evaluated Tyvaso in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approval for Roche's SMA Drug & Other Updates

Teaser: FDA approves Roche's (RHHBY) new SMA drug, Evrysdi (risdiplam).

Kinjel Shah headshot

Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes

The Zacks Large-Cap Pharmaceuticals industry ranks in the bottom 26% of more than 250 Zacks industries.

Radius' (RDUS) Q2 Earnings Miss Estimates, Sales Surpass

Radius (RDUS) reports a wider-than-expected loss but beats sales estimates in the second quarter.

Ritujay Ghosh headshot

5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism

Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.

Sweta Killa headshot

Pharma ETFs Soar on Robust Q2 Earnings

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus

Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.

The Zacks Analyst Blog Highlights: Apple, Mastercard, Eli Lilly, PetroChina and Anheuser-Busch InBev

The Zacks Analyst Blog Highlights: Apple, Mastercard, Eli Lilly, PetroChina and Anheuser-Busch InBev